Cargando…

FLT3-IRAK dual targeting: an exciting new therapeutic option guided by adaptive activation of immune response pathways

Detalles Bibliográficos
Autores principales:	Rabik, Cara A., Wang, Jiawan, Pratilas, Christine A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210206/ https://www.ncbi.nlm.nih.gov/pubmed/32395555 http://dx.doi.org/10.21037/atm.2020.01.21

Ejemplares similares

From Genes to -Omics: The Evolving Molecular Landscape of Malignant Peripheral Nerve Sheath Tumor
por: Lemberg, Kathryn M., et al.
Publicado: (2020)

IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies
por: Bennett, Joshua, et al.
Publicado: (2022)

Combination MEK and mTOR inhibitor therapy is active in models of glioblastoma
por: Schreck, Karisa C, et al.
Publicado: (2020)

Anti‐CD20 therapeutic options in immune‐mediated thrombotic thrombocytopenic purpura
por: Maitta, Robert W.
Publicado: (2022)

Luteolin as a therapeutic option for multiple sclerosis
por: Theoharides, Theoharis C
Publicado: (2009)

Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer?
por: Ricci, Angela Dalia, et al.
Publicado: (2021)

Targeting gut microbiome, is it always a therapeutic option?
por: Rodríguez-Nogales, Alba, et al.
Publicado: (2020)

Regulation of innate immune signaling by IRAK proteins
por: Pereira, Milton, et al.
Publicado: (2023)

Irak : cinco años después /
por: Rosas, María Cristina
Publicado: (2008)

Is targeting circulating T blood cells a therapeutic option for vitiligo?
por: Matos, T.R.
Publicado: (2020)

Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice
por: Annesley, Colleen E., et al.
Publicado: (2018)

Outgrowing IRAK-4
por: Bashyam, Hema
Publicado: (2007)

IRAK signalling in cancer
por: Rhyasen, G W, et al.
Publicado: (2015)

A tale of two receptors: Dual roles for ionotropic acetylcholine receptors in regulating motor neuron excitation and inhibition
por: Philbrook, Alison, et al.
Publicado: (2013)

Selective predisposition to bacterial infections in IRAK-4–deficient children: IRAK-4–dependent TLRs are otherwise redundant in protective immunity
por: Ku, Cheng-Lung, et al.
Publicado: (2007)

Polyherbal formulation as a therapeutic option to improve wound healing in the diabetic foot
por: Papanas, N., et al.
Publicado: (2011)

Promoting platelets is a therapeutic option to combat severe viral infection of the lung
por: Qiu, Jiahuang, et al.
Publicado: (2020)

Focus on Therapeutic Options for Surgically Resectable Pancreatic Adenocarcinoma Based on Novel Biomarkers
por: Olivari, Alessandro, et al.
Publicado: (2023)

HSP70 and FLT3-ITD: Targeting chaperone system to overcome drug resistance
por: Yang, Jing, et al.
Publicado: (2021)

IRAK-M regulation and function in host defense and immune homeostasis
por: Hubbard, Leah L.N., et al.
Publicado: (2010)

The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors
por: Lim, Sung Hee, et al.
Publicado: (2016)

IRAK-4 Inhibitors for Inflammation
por: Wang, Zhulun, et al.
Publicado: (2009)

There’s life in the old dog yet: vitamin C as a therapeutic option in endothelial dysfunction
por: Rodemeister, Sandra, et al.
Publicado: (2014)

Early infant growth impairment in the setting of frequent exclusive breast feeding: considering therapeutic options
por: Nankabirwa, Victoria, et al.
Publicado: (2022)

A xCT role in tumour-associated ferroptosis shed light on novel therapeutic options
por: Criscuolo, Daniela, et al.
Publicado: (2022)

Adjuvants of Immunity : Harnessing Innate Immunity to Promote Adaptive Immunity
por: Bendelac, Albert, et al.
Publicado: (2002)

The mechanism of activation of IRAK1 and IRAK4 by interleukin-1 and Toll-like receptor agonists
por: Vollmer, Stefan, et al.
Publicado: (2017)

Pathophysiology and new targets for therapeutic options in Chagas heart disease
por: Ferreira, João Marcos B Barbosa
Publicado: (2022)

Beyond adaptive immunity: induction of trained immunity by COVID-19 adenoviral vaccines
por: Netea, Mihai G., et al.
Publicado: (2023)

The excitement of Google Scholar, the worry of Google Print
por: Banks, Marcus A
Publicado: (2005)

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML
por: Wang, Aoli, et al.
Publicado: (2016)

IRAK1: oncotarget in MDS and AML
por: Beverly, Levi J., et al.
Publicado: (2014)

The dual face of NAMPT: Intracellular/extracellular protein and diagnostic/therapeutic target in cancer
por: Audrito, Valentina
Publicado: (2020)

Cirrhosis-associated immune dysfunction: Novel insights in impaired adaptive immunity
por: Liaskou, Evaggelia, et al.
Publicado: (2019)

Policing of gut microbiota by the adaptive immune system
por: Dollé, Laurent, et al.
Publicado: (2016)

Bet-hedging in innate and adaptive immune systems
por: Tate, Ann T, et al.
Publicado: (2022)

Treatment options of lymphangioma circumscriptum
por: Puri, Neerja
Publicado: (2015)

Increasing Options for First-Line Therapy in Primary FSGS?
por: Lafayette, Richard A.
Publicado: (2018)

IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel
por: Wee, Zhen Ning, et al.
Publicado: (2015)

Seeking Synchrony Between Family Planning and Immunization: A Week-10 DMPA Start Option for Breastfeeding Mothers
por: Stanback, John
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_6acqlen5vac71iof2q5djhq9c6